DPP4 and atrial fibrillation: The CVD-REAL Nordic, an observational cohort study, failed to identify any difference in AF risk between dapagliflozin and DPP4 inhibitors (HR: 0.92; 95% CI, 0.76–1.12) (Persson et al., 2018).